 GlycoMimetics NASDAQ:GLYC was downgraded by Zacks Investment Research from a buy rating to a hold rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays ... 